Clinical Trial Update: Safety and Efficacy of Apligraf in Nonhealing Wounds of Subjects With Junctional or Dystrophic Epidermolysis Bullosa (EB) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Apligraf for nonhealing wounds in patients with epidermolysis bullosa (junctional or dystrophic) was terminated, with results posted in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epidermolysis Bullosa Dystrophic
• Epidermolysis Bullosa Junctional

Drugs mentioned

• Apligraf

Snippet

Sponsor: Organogenesis | Conditions: Epidermolysis Bullosa, Junctional, Epidermolysis Bullosa Dystrophica | Phase 3 | Status: TERMINATED | Results posted: 2010-06-22